Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND Elotuzumab plus lenalidomide and dexamethasone has shown improved progression-free and overall survival versus lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. We aimed to assess these regimens in patients with newly diagnosed multiple myeloma who are ineligible for haematopoietic stem-cell transplantation (HSCT). METHODS ELOQUENT-1 is an open-label, multicentre, randomised, phase 3 trial conducted at 185 hospitals, oncology practices, and research centres in 19 countries. Eligible patients were aged 18 years or older with newly diagnosed, untreated, symptomatic myeloma and not candidates for high-dose therapy plus HSCT, and an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower. Patients were randomly assigned (1:1) to receive elotuzumab plus lenalidomide and dexamethasone or lenalidomide and dexamethasone using an interactive voice response system, stratified by the International Staging System (ISS; stage I-II vs III), age (<75 years vs ≥75 years), and ECOG performance status (0 vs 1-2). Patients in the elotuzumab plus lenalidomide and dexamethasone group received elotuzumab administered intravenously at 10 mg/kg on days 1, 8, 15, and 22 during cycles 1 and 2, days 1 and 15 during cycles 3-18, and then at 20 mg/kg on day 1 for subsequent cycles. In both treatment groups, patients received 25 mg lenalidomide orally on days 1-21 of each cycle and 40 mg dexamethasone on days 1, 8, 15, and 22 of each cyc…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Self-citationKumar, S. K., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., et al. (2014) · Leukemia · doi:10.1038/leu.2013.313 · Cited by 1,369
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
Self-citationOral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516282 · Cited by 1,060 · cited 1×
“27,28 Similarly, ixazomib plus Rd (IRd) significantly improved progression-free survival versus placebo plus Rd in the relapsed/refractory setting, 29 but not in newly diagnosed patients in TOURMALINE-MM2.”
Self-citationDaratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,045 · cited 1×
“…the SWOG S0777 and MAIA studies have demonstrated significantly improved progression-free survival with VRd and DRd, respectively, versus Rd. 11,12 Differences in the mechanism of action of these agents may account for the enhanced efficacy and/or synergy of these regimens compared with other…”
Self-citationDurie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793 · cited 1×
“7,8 9-12 Elotuzumab is a humanized immunoglobulin G1 immunostimulatory monoclonal antibody that targets signalling lymphocytic activation molecule family member 7, a glycoprotein highly expressed on myeloma cells, natural killer (NK) cells, and some immune cells, but not on other normal tissues.”
Self-citationKumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721
Self-citationIMWG consensus on risk stratification in multiple myeloma
Chng, W. J., Dispenzieri, A., Chim, C.-S., Fonseca, R., Goldschmidt, H., Lentzsch, S., Munshi, N., Palumbo, A., Miguel, J. S., Sonneveld, P., et al. (2014) · Leukemia · doi:10.1038/leu.2013.247 · Cited by 601
Self-citation
Cited by
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 162
Dimopoulos, M. A., Dytfeld, D., Grosicki, S., Moreau, P., Takezako, N., Hori, M., Leleu, X., LeBlanc, R., Suzuki, K., Raab, M. S., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.21.02815 · Cited by 114
Self-citationMultiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
Therapeutic Antibodies in Medicine
Sharma, P., Joshi, R. V., Pritchard, R., Xu, K., & Eicher, M. A. (2023) · Molecules · doi:10.3390/molecules28186438 · Cited by 90
Perspectives on the Treatment of Multiple Myeloma
Rafae, A., van Rhee, F., & Hadidi, S. A. (2023) · The Oncologist · doi:10.1093/oncolo/oyad306 · Cited by 74
Metadata
- Authors
- Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., Magen, H., Larocca, A., Laubach, J. P., Petrucci, M. T., Reece, D., White, D., Mateos, M.-V., Špička, I., Lazaroiu, M., Berdeja, J., Kaufman, J. L., Jou, Y.-M., Ganetsky, A., Popa McKiver, M., Lonial, S., Weisel, K., Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., Magen, H., Larocca, A., Laubach, J. P., Petrucci, M. T., Reece, D., White, D., Mateos, M.-V., Špička, I., Lazaroiu, M., Berdeja, J., Kaufman, J. L., Jou, Y.-M., Ganetsky, A., Popa McKiver, M., Lonial, S., Weisel, K., Sandhu, I., Podhorecka, M., Palumbo, A., Shacham-Abulafia, A., Vaxman, I., Shpilberg, O., Besemer, B., Martelli, M., Foà, R., De Fabritiis, P., Caravita di Toritto, T., Gheorghita, E., Oriol, A., Rowlings, P., Emanuele, A., Carella, A. M., Offidani, M., Bladé, J., Casado, L. F., Oakervee, H., Panelli, V., Meza, L., Kühr, T., Granell, M., Benson, D., Nair, R., Holden, V., Reeves, J., Eek, R. W., Walker, P. A., Catalano, J., Rosta, A., Lech-Marańda, E., Samaras, C., Reiman, A., Weaver, R., Acs, P., Grigg, A., De Prijck, B., Louzada, M., Minuk, L., Sebag, M., Klausmann, M., Welslau, M., Hellmann, A., Danaila, C., Becker, P., Bensinger, W., Porterfield, B., Modiano, M., Schultz, S. M., Manges, R., Lee, H.-S. C., Gray, J. X., Wright, M. P., Vekemans, M.-C., Hamed, A., Gasztonyi, Z., Mikala, G., Masszi, T., Gamberi, B., Kuliczkowski, K., Usnarska-Zubkiewicz, L., Bengoechea, E., Gutiérrez, M. A., García, M. T., San-Miguel, J., Driessen, C., Behl, R., Brenner, W., Gray, C., Hansen, V., Moezi, M., Cortes, H. V., Yen, C., Gressot, L., Horvath, N., D'Rozario, J. M., Latimer, M., Kyrtsonis, M.-C., Chubar, E., Mittelman, M., Baldini, L., Tosi, P., Vacca, A., Jędrzejczak, W. W., Robak, T., Lahuerta, J. J., Carney, J., Chen, F., Hirsch, R., Ruiz, M., Alencar, A., Jagasia, M., Kasbari, S., Kuriakose, P., Mahmood, A., Chaudhry, M., Cohen, G., Noga, S., Roa, S., Jakubowiak, A., Rosenbaum, C., Delforge, M., Delrieu, V., Doyen, C., Dries, D., Demuynck, H., Schots, R., Maisnar, V., Blau, I. W., Dürk, H. A., Kerkhoff, A., Kropff, M., Munder, M., Röllig, C., Scheid, C., Symeonidis, A. S., Illés, Á., Coyne, M., O'Gorman, P., Hayden, P., O'Dwyer, M., Ben-Yehuda, D., Braester, A., Nemets, A., Lugassy, G., Cohen, Y., Rahimi-Levene, N., Bosi, A., Pezzatti, S., Rossini, F., Pogliani, E. M., Pinto, A., Komarnicki, M., Borsaru, G., Stoia, R., Afanasyev, B., Goñi, M. A., Carboneras, A. V., Ali, S., Rubenstein, S. E., Caputto, S., Cosgriff, T., Fanning, S., Khojasteh, A., Liman, A., Malcolm, A., Vrindavanam, N., Patel, R., Belani, R., Shieh, M., Stockerl-Goldstein, K., Strnad, C., Stuart, R., Chhabra, S., Costa, L., Jhangiani, H., Augustson, B., Filshie, R., Johnston, A., Hertzberg, M. S., Mineur, P., Fox, S., Kotb, R., Dao, V., LeBlanc, R., Gregora, E., Brioli, A., Mügge, L.-O., Hänel, M., Langer, C., Kapsali, E., Briasoulis, E., Kyriakou, D., Hardan, I., Horowitz, N. A., Clotilde, C., Fabbiano, F., Castagnari, B., Ciceri, F., Musuraca, G., Deptała, A., Kłoczko, J., Balea, M., Vladareanu, A.-M., Rossiev, V., Alegre, A., Encinas, C., Gayoso, J., Pabst, T., Rabin, N., Arledge, S., Cabanillas, F., Catlett, J., Chidiac, T., Clarkson, D., Dhodapkar, M., Geils, G., Khan, C. M., Sahovic, E., Khasawneh, M., Sehgal, R., Ballester, O., Levy, M., Fay, J., Liem, K., Lunning, M., Vose, J., Faber, E., MacFarlane, D., Hohl, R., Mahmood, T., Bhaskar, B., Mims, M., Oliff, I., Paner, A., Maciejewski, J., Padmanabhan, A., Richard, R., Sanyal, A., Schiller, G., Staszewski, H., Stevens, D., Vaughn, C., & Windsor, K.
- Affiliations
- Instituto de Investigación Biomédica de Salamanca (ES)
- Princess Margaret Cancer Centre (CA)
- University of Alberta (CA)
- Heidelberg University (DE)
- Istituto di Ematologia di Bologna (IT)
- Dana-Farber Cancer Institute (US)
- ORCID
- Sandhu, Irwindeep
- Podhorecka, Monika
- Vaxman, Iuliana
- Shpilberg, Ofer
- Martelli, Maurizio
- Oriol, Albert
- Carella, Angelo M
- Offidani, Massimo
- Bladé, Joan
- Casado, Luis F
- Benson, Don
- Eek, Richard W
- Walker, Patricia A
- Grigg, Andrew
- Louzada, Martha
- Minuk, Leonard
- Welslau, Manfred
- Hellmann, Andrzej
- Danaila, Catalin
- Becker, Pamela
- Mikala, Gábor
- Masszi, Tamás
- Gamberi, Barbara
- Kuliczkowski, Kazimierz
- Driessen, Christoph
- Horvath, Noemi
- Latimer, Maya
- Mittelman, Moshe
- Baldini, Luca
- Tosi, Patrizia
- Vacca, Angelo
- Robak, Tadeusz
- Lahuerta, Juan J
- Chen, Franklin
- Ruiz, Marco
- Alencar, Alvaro
- Jagasia, Madan
- Kasbari, Samer
- Kuriakose, Philip
- Noga, Stephen
- Jakubowiak, Andrzej
- Rosenbaum, Cara
- Delforge, Michel
- Doyen, Chantal
- Blau, Igor W
- Kerkhoff, Andrea
- Munder, Markus
- Röllig, Christoph
- Scheid, Christof
- Symeonidis, Argiris S
- Illés, Árpád
- Coyne, Mark
- Hayden, Patrick
- O'Dwyer, Michael
- Braester, Andrei
- Cohen, Yossi
- Bosi, Alberto
- Pezzatti, Sara
- Komarnicki, Mieczysław
- Afanasyev, Boris
- Khojasteh, Ali
- Belani, Rajesh
- Stockerl-Goldstein, Keith
- Stuart, Robert
- Chhabra, Saurabh
- Augustson, Bradley
- Hertzberg, Mark S
- LeBlanc, Richard
- Brioli, Annamaria
- Hänel, Mathias
- Langer, Christian
- Kapsali, Eleni
- Briasoulis, Evangelos
- Horowitz, Netanel A
- Ciceri, Fabio
- Musuraca, Gerardo
- Deptała, Andrzej
- Alegre, Adrián
- Encinas, Cristina
- Gayoso, Jorge
- Pabst, Thomas
- Rabin, Neil
- Cabanillas, Fernando
- Dhodapkar, Madhav
- Sehgal, Rajesh
- Levy, Moshe
- Lunning, Matthew
- Vose, Julie
- MacFarlane, Donald
- Mahmood, Tariq
- Maciejewski, John
- Richard, Robert
- Schiller, Gary
- Staszewski, Harry
- Venue
- The Lancet Haematology
- Publisher
- Elsevier BV
- Published
- 2022-06
- Volume
- 9
- Issue
- 6
- Pages
- e403-e414
- ISSN
- 2352-3026 (ISSN-L)
- OpenAlex
- W4229458082
- Semantic Scholar
- e23cdaf1deb653faf56db4f8baac860454a4275c
- Cited by
- 48
- References
- 29
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 15 · 2023: 12 · 2022: 8
- FWCI
- 7.82
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet Haematology (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Bern Open Repository and Information System (University of Bern) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Open Access CRIS of the University of Bern
- Funders
- Bristol-Myers Squibb Co Summit
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- elotuzumab, lenalidomide, dexamethasone, newly diagnosed multiple myeloma, progression-free survival, overall survival, CD117, CXCR4, myeloma treatment, International Staging System, ECOG performance status
- MeSH terms
- Lenalidomide, Aged, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Male, Multiple Myeloma, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. https://app.cochat.ai/papers/10.1016/s2352-3026(22)00103-x
- The paper
- Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., Magen, H., Larocca, A., Laubach, J. P., Petrucci, M. T., Reece, D., White, D., Mateos, M.-V., Špička, I., Lazaroiu, M., . . . Windsor, K. (2022). Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(22)00103-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.